U.S. Markets
Pfizer (PFE) announces that the US FDA has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
